The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

OBJECTIVES: To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with active, refractory systemic lupus erythematosus (SLE). METHODS: Twelve patients received a median of two (range 1–...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Tobias, Sarfert, Ramona, Klotsche, Jens, Kühl, Anja A, Rubbert-Roth, Andrea, Lorenz, Hannes-Martin, Rech, Jürgen, Hoyer, Bimba F, Cheng, Qingyu, Waka, Aderajew, Taddeo, Adriano, Wiesener, Michael, Schett, Georg, Burmester, Gerd-Rüdiger, Radbruch, Andreas, Hiepe, Falk, Voll, Reinhard E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484251/
https://www.ncbi.nlm.nih.gov/pubmed/25710470
http://dx.doi.org/10.1136/annrheumdis-2014-206016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484251/
https://www.ncbi.nlm.nih.gov/pubmed/25710470
http://dx.doi.org/10.1136/annrheumdis-2014-206016

Ejemplares similares